MedTrace Logo

Safety, Tolerability and Pharmacokinetics of EB-203 Eye Drops in Healthy Volunteers

NCT05538949 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2023-02-23

No results posted yet for this study

Summary

The purpose of study is to evaluate safety, tolerability and pharmacokinetics of EB-203 Drops in adult healthy volunteers.

condition/disease : AMD(Age-related Macular Degeneration) Intervention/treatment : EB-203 or Placebo Phase : Phase I

Conditions

  • Healthy

Interventions

DRUG

EB-203

* Single dose : EB-203 1%, 2%, 4%, 8% 1Drop, QD / Day1. * Multiple dose : EB-203 1%, 2%, 4%, 8% 1Drop, BID / Day5\~Day8.

DRUG

Placebo

Placebo 1Drop, QD / Day1, BID / Day5\~Day8.

Sponsors & Collaborators

  • EyebioKorea, Inc.

    lead INDUSTRY

Principal Investigators

  • Jong-Lyul Ghim · Busan Paik Hospital, Inje University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-06-29
Primary Completion
2022-10-07
Completion
2022-10-07

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05538949 on ClinicalTrials.gov